Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2022 Earnings Call Transcript

Amylyx Prescription drugs, Inc. (NASDAQ:AMLX) This autumn 2022 Earnings Convention Name March 13, 2023 4:30 PM ET

Firm Members

Lindsey Allen – Head of Investor Relations and Communications

Justin Klee – Co-Chief Govt Officer and Co-Founder

Margaret Olinger – World Head of Industrial and CCO

James Frates – Chief Monetary Officer

Josh Cohen – Co-Chief Govt Officer and Co-Founder

Convention Name Members

Geoff Meacham – Financial institution of America

Umer Raffat – Evercore ISI

Neena Bitritto-Garg – Citi

Corinne Jenkins – Goldman Sachs

Marc Goodman – SVB Securities

Ananda Ghosh – H.C. Wainwright


Good afternoon. My identify is Gary, and I will probably be your convention operator at the moment. At the moment, I wish to welcome everybody to the Amylyx Prescription drugs Fourth Quarter and Full 12 months 2022 Earnings Convention Name. All contributors will probably be in a listen-only mode. After at the moment’s presentation, there will probably be a chance to ask questions. [Operator Instructions] Please be suggested that this name is being recorded on the firm’s request.

I might now like to show the decision over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed.

Lindsey Allen

Good afternoon and thanks for becoming a member of us at the moment to debate our fourth quarter and full 12 months 2022 earnings. With me on the decision are Josh Cohen and Justin Klee, our Co-CEOs; Margaret Olinger, our Chief Industrial Officer; and Jim Frates, our Chief Monetary Officer.

Earlier than we start, I wish to remind everybody that any statements we make or data introduced on this name that aren’t historic information are forward-looking statements which are primarily based on our present beliefs, plans and expectations, and are made pertinent to the Secure Harbor provisions of the Non-public Securities Litigation Reform Act of 1995.These statements embody, however will not be restricted to our expectations with respect to RELYVRIO and ALBRIOZA, statements relating to regulatory developments and the